Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted
based on clinical features, leukemia genomics and minimal residual disease (MRD); …

Genomic analyses and MRD should be used together for risk-directed treatment of
childhood ALL. Six recently described subtypes— DUX4 -rearranged, PAX5alt, BCR–ABL1 -like, …

Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL),
and resistance to glucocorticoids in leukemia cells confers poor prognosis. To elucidate …

Background Outcomes for children with relapsed or refractory acute myeloid leukaemia remain
poor. The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with …

Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major
adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors …

Childhood, adolescent, and young adult cancer survivors are at increased risk of reduced
bone mineral density. Clinical practice surveillance guidelines are important for timely …

PURPOSE Pegaspargase (PEG-ASP) has largely replaced native Escherichia coli asparaginase
(L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life …

Identification of genomic and epigenomic determinants of drug resistance provides important
insights for improving cancer treatment. Using agnostic genome-wide interrogation of …

Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity
reactions can lead to suboptimal asparaginase exposure. Our objective was to use a …

T cells expressing CD19-specific chimeric antigen receptors (CD19-CARs) have potent
antileukemia activity in pediatric and adult patients with relapsed and/or refractory B-cell acute …